June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Controlled Release of Adeno-Associated Viruses (AAVs) Using Hydrogel Implants Improve GFP Expression and Reduce Anti-Drug Antibody (ADA) Titers and Inflammation in Rabbits
Author Affiliations & Notes
  • Meryem Pehlivaner
    Ocular Therapeutix Inc, Bedford, Massachusetts, United States
  • Steven Lu
    Ocular Therapeutix Inc, Bedford, Massachusetts, United States
  • Nelson Bello
    Ocular Therapeutix Inc, Bedford, Massachusetts, United States
  • Rabia Gurses Ozden
    Ocular Therapeutix Inc, Bedford, Massachusetts, United States
  • Rami El Hayek
    Ocular Therapeutix Inc, Bedford, Massachusetts, United States
  • Charles D Blizzard
    Ocular Therapeutix Inc, Bedford, Massachusetts, United States
  • Peter K Jarrett
    Ocular Therapeutix Inc, Bedford, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Meryem Pehlivaner Ocular Therapeutix, Code E (Employment); Steven Lu Ocular Therapeutix, Code E (Employment); Nelson Bello Ocular Therapeutix, Code E (Employment); Rabia Gurses Ozden Adverum, Code C (Consultant/Contractor), Ocular Therapeutix, Code E (Employment); Rami El Hayek Ocular Therapeutix, Code E (Employment); Charles Blizzard Ocular Therapeutix, Code E (Employment); Peter Jarrett Ocular Therapeutix, Code E (Employment)
  • Footnotes
    Support  Study sponsor: Ocular Therapeutix
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 802. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Meryem Pehlivaner, Steven Lu, Nelson Bello, Rabia Gurses Ozden, Rami El Hayek, Charles D Blizzard, Peter K Jarrett; Controlled Release of Adeno-Associated Viruses (AAVs) Using Hydrogel Implants Improve GFP Expression and Reduce Anti-Drug Antibody (ADA) Titers and Inflammation in Rabbits. Invest. Ophthalmol. Vis. Sci. 2023;64(8):802.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : AAV ocular gene therapies can elicit inflammation and an immune response that can be detrimental to the efficacy of treatment. This study tested the hypothesis that modulating the pharmacokinetics of AAV delivery via a degradable hydrogel implant can reduce the risk of developing severe ocular inflammation and improve transgene expression by lowering vector copies and ADA titers in blood.

Methods : AAV2.7m8-CMV-GFP loaded hydrogel implants at a dose of 3.6E+10 GC/implant were formulated to release AAVs over 4 (Fast Release) or 14 days (Medium Release). A single implant was injected intravitreally in both eyes of New Zealand White rabbits. Bilateral injections of a bolus 50µL AAV solution at the same dose were performed as a positive control. The impact of sustained AAV delivery on inflammation and green fluorescent protein (GFP) expression was investigated through ocular examinations, fundus autofluorescence (FAF) imaging, and enzyme-linked immunoassay (ELISA) quantification in ocular tissues (n=3 rabbits/6 eyes per group). Vector genomes in plasma were quantified by quantitative polymerase chain reaction and ADA titers in serum were determined by ELISA.

Results : FAF imaging and protein quantification demonstrated greatest GFP expression in the Medium release group compared to the Bolus and Fast release groups (Figure 1). The Medium release group also resulted in lower peak inflammation at Week 3 and lower ADA titer levels at Week 13 compared to the other groups (Figure 2A & 2B). Using a controlled release strategy can also lower systemic levels of AAV as evidenced by lower copy numbers from the AAV implant groups in plasma (Figure 2C).

Conclusions : In this study, we show that modulating AAV pharmacokinetics from hydrogel implants can impact ocular inflammation, adaptive immune response, and transgene protein expression. These data demonstrate that sustained release of AAVs provides an avenue to improve ocular gene therapies.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

Figure 1. Quantification of GFP in rabbit ocular tissues via ELISA and representative Week 12 FAF images.

Figure 1. Quantification of GFP in rabbit ocular tissues via ELISA and representative Week 12 FAF images.

 

Figure 2. Effect of controlled release of AAVs on (A) inflammation-aqueous cells, (B) ADA titers, and (C) vector shedding.

Figure 2. Effect of controlled release of AAVs on (A) inflammation-aqueous cells, (B) ADA titers, and (C) vector shedding.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×